TABLE 4.
Summary of adverse events reported within 48 h after initial or optional second dose (safety population)
| Pooled ACHIEVE participants | ||
|---|---|---|
| Placebo | Ubrogepant 50 mg | |
| (n = 984) | (n = 954) | |
| Triptan responders | 372 | 354 |
| All TEAEs, n (%) | 37 (9.9) | 38 (10.7) |
| Treatment‐related TEAEs | 21 (5.6) | 26 (7.3) |
| All serious AEs, n (%) | 0 | 0 |
| Triptan‐insufficient responders | 239 | 240 |
| All TEAEs, n (%) | 29 (12.1) | 37 (15.4) |
| Treatment‐related TEAEs | 14 (5.9) | 25 (10.4) |
| All serious AEs, n (%) | 0 | 0 |
| Triptan naive | 373 | 360 |
| All TEAEs, n (%) | 47 (12.6) | 32 (8.9) |
| Treatment‐related TEAEs | 36 (9.7) | 18 (5.0) |
| All serious AEs, n (%) | 0 | 0 |
Abbreviations: AE, adverse event; TEAE, treatment‐emergent adverse event.